A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary
efficacy of mavacamten treatment on biomarkers levels in participants with heart failure with
preserved ejection fraction (HFpEF) and chronic elevation of cTnI and/or NT-proBNP. Data from
this study will inform future study designs of mavacamten in participants with HFpEF.